drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
A humanized anti-CD2 monoclonal antibody (TCD601) that binds CD2 on T cells and NK cells, blocks CD2–LFA-3 (CD58) costimulatory signaling, induces lymphocyte depletion with preferential reduction of CD2high effector/memory T cells, and aims to shift T-cell phenotypes toward a more regulatory profile to preserve β-cell function in recent-onset type 1 diabetes.
nci_thesaurus_concept_id
C38685
nci_thesaurus_definition
A humanized monoclonal immunoglobulin G1 antibody with potential antineoplastic activity. Siplizumab binds to CD2, a specific receptor found in T cells and NK cells, thereby triggering a host immune response that results in lysis of CD2+ cells, selective suppression of the immune system, and control of activated T cell growth.
drug_mesh_term
Siplizumab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Unknown
drug_mechanism_of_action
Humanized IgG1 anti-CD2 monoclonal antibody that binds CD2 on T cells and NK cells, blocks CD2–CD58 (LFA-3) costimulatory signaling, and engages Fc-mediated effector functions (e.g., ADCC/CDC) to deplete CD2+ lymphocytes—preferentially CD2high effector/memory T cells—shifting the T-cell compartment toward a more regulatory phenotype and suppressing pathogenic T-cell activity.
drug_name
Siplizumab
nct_id_drug_ref
NCT05574335